Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)
National Institutes of Health · Opportunity PAR-08-025
Multiple Receipt Dates - See Link to Full Announcement for details.
Who can apply
- State governments
- Public and State institutions of higher education
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply.
About this opportunity
-Purpose. This FOA is intended to promote translational research in new agent/modality development with timely exploitation of new cancer-relevant therapeutic and/or preventive strategies that involve defined molecular targets. Applications are solicited for pilot clinical trials exploring individual anticancer agents/modalities and/or their combinations in the context of specific molecular targets. Applicants may propose Phase 0, Phase I, Phase II, and/or other pilot cancer clinical trials. In addition, patient monitoring and laboratory correlative studies related to clinical trials may be proposed. Applications that explore complementary and alternative approaches for cancer prevention and/or treatment are also encouraged. Clinical trials proposed may be oriented on AIDS-associated malignancies and cancer-related nutritional interventions. Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application. -Mechanism of Support. This FOA will use the NIH exploratory/developmental (R21) grant mechanism for exploratory, pilot projects. Applicants planning to propose fully developed research projects supported by preliminary data should consider a related FOA (PA-07-356) that solicits applications for clinical therapeutic and preventive trials under the NIH research project (R01) grant mechanism. -Funds Available and Anticipated number of Awards: Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | National Institutes of Health | August 18, 2026 23d left | — | Nonprofits |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | $499k | Nonprofits |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |